Rapt Therapeutics Inc (RAPT)

$8.72

-0.52

(-5.63%)

Market is closed - opens 8 PM, 26 Feb 2024

Insights on Rapt Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.4% return, outperforming this stock by 143.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 241.3% return, outperforming this stock by 295.0%

Performance

  • $8.63
    $9.46
    $8.72
    downward going graph

    1.03%

    Downside

    Day's Volatility :8.8%

    Upside

    7.85%

    downward going graph
  • $6.86
    $31.45
    $8.72
    downward going graph

    21.33%

    Downside

    52 Weeks Volatility :78.19%

    Upside

    72.27%

    downward going graph

Returns

PeriodRapt Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-36.95%
12.8%
0.0%
6 Months
-54.08%
10.8%
0.0%
1 Year
-69.92%
15.1%
-6.4%
3 Years
-53.74%
30.2%
-19.6%

Highlights

Market Capitalization
317.8M
Book Value
$5.03
Earnings Per Share (EPS)
-2.89
Wall Street Target Price
31.75
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-36.13%
Return On Equity TTM
-60.13%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
1.5M
EBITDA
-117.1M
Diluted Eps TTM
-2.89
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.11
EPS Estimate Next Year
-3.44
EPS Estimate Current Quarter
-0.75
EPS Estimate Next Quarter
-0.78

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Rapt Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
16
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 264.11%

Current $8.72
Target $31.75

Technicals Summary

Sell

Neutral

Buy

Rapt Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Rapt Therapeutics Inc
Rapt Therapeutics Inc
-63.58%
-54.08%
-69.92%
-53.74%
-32.92%
Moderna, Inc.
Moderna, Inc.
-6.18%
-13.82%
-30.24%
-34.99%
345.54%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.41%
18.17%
29.48%
116.51%
133.41%
Novo Nordisk A/s
Novo Nordisk A/s
16.81%
32.44%
72.22%
241.3%
399.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.03%
22.87%
49.66%
101.95%
130.83%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Rapt Therapeutics Inc
Rapt Therapeutics Inc
NA
NA
NA
-3.11
-0.6
-0.36
NA
5.03
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.46
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.77
27.77
1.97
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.7
45.7
4.49
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.77
30.77
0.58
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Rapt Therapeutics Inc
Rapt Therapeutics Inc
Buy
$317.8M
-32.92%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.9B
345.54%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$105.9B
133.41%
27.77
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.7B
399.49%
45.7
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$110.2B
130.83%
30.77
36.68%

Institutional Holdings

  • FMR Inc

    13.08%
  • T. Rowe Price Associates, Inc.

    10.29%
  • Column Group LLC

    7.79%
  • BlackRock Inc

    6.74%
  • Vanguard Group Inc

    5.88%
  • Perceptive Advisors LLC

    5.58%

Corporate Announcements

  • Rapt Therapeutics Inc Earnings

    Rapt Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

rapt therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. rapt has discovered and advanced two unique drug candidates, flx475 and rpt193, each targeting c-c motif chemokine receptor 4 (ccr4), for the treatment of cancer and inflammation, respectively. the company is also pursuing a range of targets that are in the discovery stage of development.

Organization
Rapt Therapeutics Inc
Employees
129
CEO
Dr. Brian Russell Wong M.D., Ph.D.
Industry
Health Technology

FAQs